Glonghui, January 8 | Truist Securities states that the biopharmaceutical Industry in 2024 is disappointing in terms of mergers and acquisitions; the Industry requires larger/more merger transactions to recover. Truist downgraded Merck's rating from "Buy" to "Hold," with the Target Price lowered from $130 to $110. (Glonghui)
大行评级｜Truist：生物制药行业需要更多并购交易才能复苏 下调默克目标价至110美元
Major banks rating | Truist: The biopharmaceutical Industry needs more mergers and acquisitions to recover, lowering Merck's Target Price to $110.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha